Contrasting Data Knights Acquisition (NASDAQ:DKDCA) and U.S. Stem Cell (OTCMKTS:USRM)

Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) and U.S. Stem Cell (OTCMKTS:USRM – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Data Knights Acquisition and U.S. Stem Cell’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Data Knights Acquisition	N/A	N/A	$340,000.00	$0.03	364.67
U.S. Stem Cell	$80,000.00	20.67	-$2.86 million	N/A	N/A

Data Knights Acquisition has higher earnings, but lower revenue than U.S. Stem Cell.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Data Knights Acquisition and U.S. Stem Cell, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Data Knights Acquisition	0	0	0	0	N/A
U.S. Stem Cell	0	0	0	0	N/A

Institutional and Insider Ownership

78.5% of Data Knights Acquisition shares are held by institutional investors. 23.1% of Data Knights Acquisition shares are held by insiders. Comparatively, 16.7% of U.S. Stem Cell shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Data Knights Acquisition has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Comparatively, U.S. Stem Cell has a beta of -0.56, meaning that its stock price is 156% less volatile than the S&P 500.

Profitability

This table compares Data Knights Acquisition and U.S. Stem Cell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Data Knights Acquisition	N/A	-4.45%	0.35%
U.S. Stem Cell	-3,487.69%	N/A	-2,522.35%

Summary

Data Knights Acquisition beats U.S. Stem Cell on 6 of the 8 factors compared between the two stocks.

About Data Knights Acquisition

(Get Rating)

Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.

About U.S. Stem Cell

(Get Rating)

U.S. Stem Cell, Inc. is a biotechnology company, which engages in the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product, MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.